Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02996266 · ClinicalTrials.gov registry record · NA

Impact of Fever Prevention in Brain Injured Patients

A NA study, sponsored by C. R. Bard.

Terminated
Registry status
NA
Development phase
686
Enrollment target

NCT02996266: Clinical Trial NA study, sponsored by C. R. Bard.

NCT02996266 is a NA study that was terminated before completion, run by C. R. Bard. The registered enrollment target is 686 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (51% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02996266, a NA study, was terminated before completion, sponsored by C. R. Bard.

TERMINATED
Registry status
NA
Development phase
686 participants
Enrollment target

Study Summary

This study will assess the impact of fever prevention on fever burden and short- and long-term neurologic outcomes in brain injured patients. Half of the subjects will undergo fever prevention using a targeted temperature management system and half of the subjects will be treated for fever should it develop.

Primary Outcome

Daily average fever burden (°C-hour)

Interventions

  • OTHER Standard Care
  • DEVICE Targeted Temperature Management

Trial Details

FieldValue
Enrollment Target 686 participants
Start Date 2017-01
Est. Completion 2022-05-12
Phase NA
C. R. Bard

75 total trials

Why NCT02996266 stopped before completion

NCT02996266 is an interventional study that assigns participants to a tested intervention. The registered 686 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (51% lower).

The record links to 0 conditions, and to 2 interventions - of which Standard Care is the first listed.

NCT02996266 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02996266 about?

NCT02996266 is a clinical study titled "Impact of Fever Prevention in Brain Injured Patients". This study will assess the impact of fever prevention on fever burden and short- and long-term neurologic outcomes in brain injured patients. Half of the subjects will undergo fever prevention using a targeted temperature management system and half of the subjects will be treated for fever should it...

What is the current status of trial NCT02996266?

This trial is currently terminated. It is a NA study. The enrollment target is 686 participants. The study started on 2017-01. Estimated completion is 2022-05-12.

What interventions are being tested in trial NCT02996266?

The interventions under investigation include: Standard Care (OTHER), Targeted Temperature Management (DEVICE).

Who is sponsoring clinical trial NCT02996266?

This trial is sponsored by C. R. Bard, which has 75 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02996266's enrollment target sits among peer trials

686 151st of 2000 higher than 1,850 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04333537 · 686 participants · Phase 2

    Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

  • NCT06459180 · 686 participants · Phase 3

    A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

  • NCT06618274 · 686 participants · NA

    Effectiveness of Central Oncology Navigation and the Use of an ORN

  • NCT06899126 · 686 participants · Phase 3

    Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02996266, the US trial registry maintained by the National Library of Medicine. NCT02996266 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.